[Clofibrate for the treatment of hyperbilirubinemia in neonates born at term: a double blind controlled study (author's transl)].

Abstract

A double blind controlled study of the therapeutic effect of clofibrate, an inductor of bilirubin glucuronyl transferase, was performed in neonates born at term and presenting with physiologic jaundice. 47 children were treated with a single oral dose of clofibrate. 46 control children were given corn oil alone. Results show that mean plasma bilirubin levels are significantly lower in the treated group as compared with the control group, from the 16th hour of treatment, if there is no ABO incompatibility. Clofibrate treatment also resulted in a shorter duration of jaundice and a restricted use of phototherapy. No undesirable side-effect was observed.

• Authors: A Lindenbaum, X Hernandorena, M Vial, C Benattar, J C Janaud, M Dehan, A Foliot, R Leluc, J C Gabilan
• Journal: Archives francaises de pediatrie (Arch Fr Pediatr) Vol. 38 Suppl 1 Pg. 867-73 (Dec 1981) ISSN: 0003-9764 [Print] France
• Vernacular Title: Traitement curatif de l'ictère du nouveau-né à terme par le clofibrate. Essai thérapeutique contrôlé en double aveugle.
• PMID: 7036932 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ABO Blood-Group System
• Clofibrate

Topics

• ABO Blood-Group System
• Blood Group Incompatibility
• Clinical Trials as Topic
• Clofibrate (administration & dosage, therapeutic use)
• Double-Blind Method
• Female
• Humans
• Infant, Newborn
• Jaundice, Neonatal (drug therapy)
• Male